Etiopathogenesis of Behcet's disease

Autoimmunity Reviews

Volumn 9, Issue 4, 2010, Pages 241-245

  Mendoza Pinto, Claudia ^a   García Carrasco, Mario ^a,b   Jiménez Hernández, Mario ^a,e   Jiménez Hernández, Cesar ^a,e   Riebeling Navarro, Carlos ^c   Nava Zavala, Arnulfo ^a   Vera Recabarren, Mauricio ^d   Espinosa, Gerard ^e   Jara Quezada, Javier ^a   Cervera, Ricard ^e  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c UMAE Hospital de Pediatria CMN SXXI   (Mexico)

^d Hospital Exequiel González Cortés   (Chile)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Behcet; Etiopathogenesis; Inflammatory; Vasculitis

Indexed keywords

CYTOKINE; ENDOTHELIAL CELL ANTIBODY; FUNGUS ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; LEPTIN; VASCULOTROPIN;

BACTERIAL INFECTION; BEHCET DISEASE; BLOOD CLOTTING DISORDER; CIGARETTE SMOKING; DISEASE PREDISPOSITION; HEREDITY; HISTOPATHOLOGY; HUMAN; LEUKOCYTE ACTIVATION; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SACCHAROMYCES CEREVISIAE; STREPTOCOCCUS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VASCULITIS;

EID: 73849103894     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.10.005     Document Type: Review

References (39)

1. Suzuki K.M., and Suzuki N. Behcet's disease. Clin Exp Med 4 1 (2004 Sep) 10-20
2. Yazici H., and Esen F. Mortality in Behçet's syndrome. Clin Exp Rheumatol 26 5 Suppl 51 (2008 Sep-Oct) S138-S140
3. Calamia K.T., Wilson F.C., Icen M., Crowson C.S., Gabriel S.E., and Kremers H.M. Epidemiology and clinical characteristics of Behçet's disease in the US: a population-based study. Arthritis Rheum 61 5 (2009 May 15) 600-604
4. Demirkesen C., Tuzuner N., Mat C., et al. Clinicopathologic evaluation of nodular cutaneous lesion of Behcet's syndrome. Am J Clin Pathol 116 (2001) 341-346
5. Sakane T., Takeno M., Suzuki N., et al. Behcet's disease. N Engl J Med 341 (1999) 1284-1291
6. Mumcu G., Inanc N., Yavuz S., Direskeneli H., et al. The role of infectious agents in the pathogenesis, clinical manifestations and treatment strategies in Behcet's disease. Clin Exp Rheumatol (2007) s27-s31
7. Choukri F., Chakib A., Himmich H., et al. HLA-B*51 alleles confer predisposition to Behcet's disease in Moroccan patients. Hum Immunol 62 (2001) 180-185
8. Soto E., García R., Richaud Y., et al. Class I and II MHC polymorphisms in Mexican patients with Behcet's disease. Immunol Lett 93 (2004) 112-115
9. Verity D.H., Wallace G.R., Vaughan R.W., et al. HLA and TNF polymorphisms in ocular Behcet's disease. Tissue Antigens 54 (1999) 264-272
10. Wallace G.R., Verity D.H., Delamaine L., et al. Association with MICA alleles with Behcet's disease. Immunogenetics 49 (1999) 613-617
11. Nashida T., Hiruyama K., Nakaruma S., et al. Proliferative response of CD8+ (gamma) (delta) T cells recovered from eyes of patients with Behcet's disease recognize prenyl pyrophosphate antigens. J Neuroimmunol 130 (2002) 46-54
12. Atagunduz P., Ergun T., and Direskeneli H. MEFV mutations are increased in Behcet's disease (BD) and are associated with vascular involvement. Clin and Experimena 21 (2003) S35
13. Verity D.H., Wallece G., Seed P., et al. Soluble adhesion molecules in Behcet's disease. Ocul Immunol Inflamm 6 (1998) 81-92
14. Sari R.A., Kiziltunc A., Taysy S., et al. Levels of soluble E-selectin in patients with active Behcet ́s disease. Clin Rheumatol 24 1 (2005 Feb) 55-59 Electronic publication 2004 Aug 28
15. Kamoun M., Houman M.H., Hamzaoui A., and Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet's disease. Tissue Antigens 72 6 (2008 Dec) 581-587 Electronic publication 2008 Oct 18
16. Tunc R., Ozbakir F., Caglayan A., et al. Absence of ANCA in Behçet syndrome with large vessel involvement. Angiology 10 (2001) 260-262
17. Tokay S., Direskeneli H., Yurdakul S., et al. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford) 40 (2001) 192-195
18. Zeng X.J., Zhu W.G., Deng X.X., Tang F.L., and Dong Y. Anti-endothelial cell antibodies in systemic vasculitis: detection and correlation with disease activity. Zhonghua YiXue ZaZhi 84 19 (2004 Oct 2) 1629-1632
19. Lee K.H., Chung H.S., Kim H., et al. Human α-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behcet's disease. Arthritis Rheum 48 (2003) 2025-2035
20. Choi C.H., Kim T.I., Kim B.C., Shin S.J., Lee S.K., Kim W.H., et al. Anti-Saccharomyces cerevisiae antibodies in intestinal Behçet's disease patients: relation to clinical course. Dis Colon Rectum 49 12 (2006 Dec) 1849-1859
21. Filik L., and Biyikoglu I. Differentiation of Behcet's disease from inflammatory bowel diseases: anti-Saccharomyces cerevisiae antibody and anti-neutrophilic cytoplasmic antibody. World J Gastroenterol 14 47 (2008 Dec 21) 7271
22. Hamzaoui K., Hamzaoui A., Guemira F., et al. Cytokine profile in Behcet ́s disease, relationship with disease activity. Scand J Rheumatol 31 (2002) 205-210
23. Hamzaoui A., Ghraîri H., Ammar J., et al. IL-18 mRNA expression and IFN-γ induction in bronchoalveolar lavage from Behcet's disease. Clin Experimen 21 (2003) S-8
24. Ben Ahmed M., Houman H., Miled M., et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum 40 (2004) 2291-2295
25. Krause I., and Weinberger A. Behçet's disease. Curr Opin Rheumatol 20 1 (2008 Jan) 82-87
26. Bank I., Duvdevani M., and Livneh A. Expansion of [gamma][delta] T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 141 (2003) 33-40
27. Koarada S., Haruta Y., Tada Y., et al. Increased entry of CD4+ T cell into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet ́s disease. Rheumatology (Oxford) 43 (2004) 843-851
28. Ling E., Shubinsky G., and Press J. Increased proportion of CD3+CD4-CD8- double-negative T cells in peripheral blood of children with Behcet's disease. Autoimmun Rev 6 4 (2007 Mar) 237-240 Electronic publication 2006 Aug 28
29. Eksioglu-Demiralp E., Direskeneli H., Kibaroglu A., et al. Neutrophil activation in Behcet ́s disease. Clin Exp Rheumatol 19 (2001) S19-S24
30. Yazici C., Kose K., Calis M., et al. Increased advanced oxidation protein products in Behcet's disease: a new activity marker?. Br J Dermatol 151 (2004) 105-111
31. Pay S., Simşek I., Erdem H., and Dinç A. Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 27 5 (2007 Mar) 417-424
32. Yazici H. The lumps and bumps of Behçet's syndrome. Autoimmun Rev 3 Suppl 1 (2004 Jun) S53-S54
33. Espinosa G., Font J., Tassies D., et al. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 112 (2002) 37-43
34. Korkmaz C., Bozan B., Kosar M., et al. Is there an association of plasma homocysteine levels with vascular involvement in patients with Behçet's syndrome?. Clin Exp Rheumatol 20 suppl 26 (2002) S30-S34
35. Salvarani C., Calamia K., Silingardi M., et al. Thrombosis associated with the prothrombin G->A20210 mutation in Behcet's disease. J Rheumatol 27 (2000) 515-516
36. Navarro S., Ricart J.M., Medina P., et al. Activated protein C levels in Behcet's disease and risk of venous thrombosis. Br J Haematol 126 (2004) 550-556
37. Evereklioglu C., Inaloz H.S., Kirtak N., et al. Serum leptin concentration is increased in patients with Behcet's syndrome and is correlated with disease activity. Br J Dermatol 147 (2002) 331-336
38. Yen J.H., Tsai W.C., Lin C.H., et al. Cytochrome P450 1A1 y manganese superoxide dismutase gene polymorphisms in Behcet's disease. J Rheumatol 31 (2004) 736-740
39. Ozturk M.A., Calguneri M., Kiraz S., et al. Angiotensin-converting enzyme gene polymorphism in Behcet's disease. Clin Rheumatol 23 (2004) 142-146